The news comes during a strong market day, with the S&P 500 gaining 0.3% and the healthcare sector, where Kymera operates, up 2.2%.KYMR Stock Jumps On KT-621 Phase 2b BROADEN2 MilestoneKymera has completed enrollment in the BROADEN2 trial nearly six months ahead of schedule, allowing for an accelerated topline data readout expected by year-end 2026.The company plans to initiate Phase 3 trials for KT-621 by mid-2027, reflecting strong interest in this innovative treatment.“With enrollment now complete, we are positioned to bring forward our expected topline data readout to this year as well as accelerate our planned Phase 3 initiation, subsequent readouts, and NDA filing,” said Nello Mainolfi, Founder, President, and CEO, Kymera Therapeutics.KYMR Technical Outlook: Momentum Above Key Moving AveragesThe stock’s current price of $121.03 is significantly above its moving averages, with the 20-day simple moving average (SMA) at $85.20, indicating a bullish trend.The Relative Strength Index (RSI) is currently at 84.74, suggesting that the stock is in overbought territory, which could indicate a potential pullback in the near term.
Key Resistance: $125.00 — This level is critical as it aligns with recent swing highs and could act as a barrier to further upward movement.
